296 related articles for article (PubMed ID: 19945236)
21. A comparative study of human chorionic gonadotropin, placebo, and bed rest for women with early threatened abortion.
Harrison RF
Int J Fertil Menopausal Stud; 1993; 38(3):160-5. PubMed ID: 8348164
[TBL] [Abstract][Full Text] [Related]
22. Micronized vaginal progesterone to prevent miscarriage: a critical evaluation of randomized evidence.
Coomarasamy A; Devall AJ; Brosens JJ; Quenby S; Stephenson MD; Sierra S; Christiansen OB; Small R; Brewin J; Roberts TE; Dhillon-Smith R; Harb H; Noordali H; Papadopoulou A; Eapen A; Prior M; Di Renzo GC; Hinshaw K; Mol BW; Lumsden MA; Khalaf Y; Shennan A; Goddijn M; van Wely M; Al-Memar M; Bennett P; Bourne T; Rai R; Regan L; Gallos ID
Am J Obstet Gynecol; 2020 Aug; 223(2):167-176. PubMed ID: 32008730
[TBL] [Abstract][Full Text] [Related]
23. The Influence of Oral Dydrogesterone and Vaginal Progesterone on Threatened Abortion: A Systematic Review and Meta-Analysis.
Lee HJ; Park TC; Kim JH; Norwitz E; Lee B
Biomed Res Int; 2017; 2017():3616875. PubMed ID: 29392134
[TBL] [Abstract][Full Text] [Related]
24. Clinical observations on luteal phase inadequacy.
Taubert HD; Jürgensen O; Becker H
Bull Schweiz Akad Med Wiss; 1970 Oct; 25(4-6):586-94. PubMed ID: 4101703
[No Abstract] [Full Text] [Related]
25. Efficacy of progesterone on threatened miscarriage: Difference in drug types.
Wang XX; Luo Q; Bai WP
J Obstet Gynaecol Res; 2019 Apr; 45(4):794-802. PubMed ID: 30632226
[TBL] [Abstract][Full Text] [Related]
26. Hormone load tests in the first half of pregnancy--a diagnostic and therapeutic approach.
Gerhard I; Runnebaum B
Biol Res Pregnancy Perinatol; 1984; 5(4):157-73. PubMed ID: 6084523
[TBL] [Abstract][Full Text] [Related]
27. Progestogens in the prevention of miscarriage.
Carp HJ
Horm Mol Biol Clin Investig; 2016 Aug; 27(2):55-62. PubMed ID: 26677905
[TBL] [Abstract][Full Text] [Related]
28. Non-surgical interventions for threatened and recurrent miscarriages.
Tien JC; Tan TY
Singapore Med J; 2007 Dec; 48(12):1074-90; quiz 1090. PubMed ID: 18043834
[TBL] [Abstract][Full Text] [Related]
29. Sporadic pregnancy loss and recurrent miscarriage.
Devall AJ; Coomarasamy A
Best Pract Res Clin Obstet Gynaecol; 2020 Nov; 69():30-39. PubMed ID: 32978069
[TBL] [Abstract][Full Text] [Related]
30. Oral dydrogesterone vs. vaginal progesterone capsules for luteal-phase support in women undergoing embryo transfer: a systematic review and meta-analysis.
Barbosa MWP; Valadares NPB; Barbosa ACP; Amaral AS; Iglesias JR; Nastri CO; Martins WP; Nakagawa HM
JBRA Assist Reprod; 2018 Jun; 22(2):148-156. PubMed ID: 29488367
[TBL] [Abstract][Full Text] [Related]
31. [Expression of leukemia inhibitory factor in chorionic villi of normal early pregnancy, threatened abortion and inevitable abortion].
Wang ZJ; Xu J
Zhonghua Fu Chan Ke Za Zhi; 2006 Mar; 41(3):159-61. PubMed ID: 16640878
[TBL] [Abstract][Full Text] [Related]
32. Vaginal micronized progesterone versus intramuscular progesterone for luteal support in women undergoing in vitro fertilization-embryo transfer.
Mitwally MF; Diamond MP; Abuzeid M
Fertil Steril; 2010 Feb; 93(2):554-69. PubMed ID: 19362305
[TBL] [Abstract][Full Text] [Related]
33. Present and future aspects of dydrogesterone in prevention or treatment of pregnancy disorders: an outlook.
Schindler AE
Horm Mol Biol Clin Investig; 2016 Aug; 27(2):49-53. PubMed ID: 27662647
[TBL] [Abstract][Full Text] [Related]
34. A randomized double-blind controlled trial of the use of dydrogesterone in women with threatened miscarriage in the first trimester: study protocol for a randomized controlled trial.
Chan DM; Cheung KW; Yung SS; Lee VC; Li RH; Ng EH
Trials; 2016 Aug; 17(1):408. PubMed ID: 27534747
[TBL] [Abstract][Full Text] [Related]
35. A pairwise and network meta-analysis comparing the efficacy and safety of progestogens in threatened abortion.
Zhao H; He W; Yang Z
Int J Gynaecol Obstet; 2022 Mar; 156(3):383-393. PubMed ID: 33864694
[TBL] [Abstract][Full Text] [Related]
36. Management of threatened abortion.
Szabó I; Szilágyi A
Early Pregnancy; 1996 Dec; 2(4):233-40. PubMed ID: 9363221
[TBL] [Abstract][Full Text] [Related]
37. Correlation of human chorionic gonadotropin secretion in early pregnancy failure with size of gestational sac and placental histology.
Jouppila P; Huhtaniemi I; Herva R; Piiroinen O
Obstet Gynecol; 1984 Apr; 63(4):537-42. PubMed ID: 6700902
[TBL] [Abstract][Full Text] [Related]
38. Threatened miscarriage as a predictor of obstetric outcome.
Johns J; Jauniaux E
Obstet Gynecol; 2006 Apr; 107(4):845-50. PubMed ID: 16582121
[TBL] [Abstract][Full Text] [Related]
39. Oral dydrogesterone treatment during the first trimester of pregnancy: the prevention of miscarriage study (PROMIS). A double-blind, prospectively randomized, placebo-controlled, parallel group trial.
Walch K; Hefler L; Nagele F
J Matern Fetal Neonatal Med; 2005 Oct; 18(4):265-9. PubMed ID: 16318978
[TBL] [Abstract][Full Text] [Related]
40. The value of placental protein 13, β-human chorionic gonadotropin and progesterone in the prediction of miscarriages in threatened miscarriage patients.
Yalçin I; Taşkin S; Pabuçcu EG; Söylemez F
J Obstet Gynaecol; 2015 Apr; 35(3):283-6. PubMed ID: 25153203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
